Pharmadrug Inc.
Pharmadrug Inc.
Your view on LMLLF
Overview
What the company does, where it operates, and who runs it.
About Pharmadrug Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- David Kideckel
- Headquarters
- 77 King Street West, Toronto, ON, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- David Kideckel
- Headquarters
- 77 King Street West, Toronto, ON, CA
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs.
It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines.
It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule.
The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Pharmadrug Inc., and the rating behind it. LMLLF last traded at $0.0069; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Pharmadrug Inc.. Starting points for Pharmadrug Inc.: beta 0.34 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Pharmadrug Inc.. Pharmadrug Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Pharmadrug Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Pharmadrug Inc.. Pharmadrug Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Pharmadrug Inc. valued side by side against its closest peers. Pharmadrug Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Pharmadrug Inc., and how their positions are changing. At a $746,817 market value, institutional positions materially move Pharmadrug Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Pharmadrug Inc. executives and directors. Shares of Pharmadrug Inc. have traded between $0.0022 and $0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Pharmadrug Inc.. Pharmadrug Inc. is a $746,817 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Pharmadrug Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Pharmadrug Inc.. Coverage tracks Pharmadrug Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.